This is a working overview of AOD-9604, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-08 and is reviewed periodically as new material appears.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Total destruction of life. Destruction of only intelligent life. Degeneration. Loss of interest. However, he refuses to see these as inevitable ends. But the assumption that the only limit to the development of a civilization can be the existence of a finite amount of information, in all areas, is also false, since it is highly improbable that information in the Universe is infinite. Given these two hypotheses, Kardashev argues that there is no universal civilization (supercivilization) because highly developed civilizations lose interest in space exploration. In any case, and despite the problem of the end of civilizations, he concludes, in the light of his functional definition of the advanced civilization, that the latter must use mass and energy on fantastic scales. According to him, there is no reason to denounce the hypothesis that the expansion of the Universe would not be an effect of the intelligent activity of a supercivilization.
== Epidemiology == Sarcomas are rare cancers. The risk of a previously healthy person receiving a new diagnosis of bone cancer is less than 0.001%, while the risk of receiving a new diagnosis of soft-tissue sarcoma is between 0.0014 and 0.005%. The American Cancer Society estimates that in the United States there will be 3,970 new cases of bone sarcoma in 2023, and 13,400 new cases of soft-tissue sarcoma. Considering that the total estimated number of new cancer diagnoses (all types of cancer) is 1,958,310, this means bone sarcomas represent only 0.2% of all new cancer diagnoses (making them the 30th most common type of cancer) and soft-tissue sarcomas represent only 0.7% (making them the 22nd most common type of cancer) of all new cancer diagnoses in the US in 2023. These estimates are similar to previously reported data. Sarcomas affect people of all ages. Around 50% of bone sarcomas and 20% of soft-tissue sarcomas are diagnosed in people under the age of 35. Some sarcomas, such as leiomyosarcoma, chondrosarcoma, and gastrointestinal stromal tumor (GIST), are more common in adults than in children. Most high-grade bone sarcomas, including Ewing sarcoma and osteosarcoma, are much more common in children and young adults.
The International Cocoa Initiative involving major cocoa manufacturers established the Child Labor Monitoring and Remediation System to monitor thousands of farms in Ghana and Ivory Coast for child labor conditions, but the program reached less than 20% of the child laborers. In April 2018, the Cocoa Barometer report stated: "Not a single company or government is anywhere near reaching the sector-wide objective of the elimination of child labor, and not even near their commitments of a 70% reduction of child labor by 2020". They cited persistent poverty, the absence of schools, increasing world cocoa demand, more intensive farming of cocoa, and continued exploitation of child labor.
The plan was for existing TA units to recruit over their establishments (aided by an increase in pay for Territorials, the removal of restrictions on promotion, which had hindered recruiting, construction of better-quality barracks and an increase in supper rations) and then form second-line divisions from cadres that could be increased. The total strength of the TA was to be 440,000: the field force of the Territorial Army was to rise from 130,000 to 340,000, organized in 26 divisions, while an additional 100,000 all ranks would form the anti-aircraft section. The forming Second Line formations were given liberty to be numbered and named as they saw fit, with some using related names and numbers from the First World War e.g. the 23rd (Northumbrian) Infantry Division formed in 1939. The immediate response to this announcement was a vast surge in recruiting with 88,000 men enlisted by the end of April. The London Rifle Brigade raised a second battalion in 24 hours. On 26 April, limited conscription was introduced. This resulted in 34,500 twenty-year-old militiamen being conscripted into the regular army, initially to be trained for six months before deployment to the forming second-line units. In parallel, recruits continued to surge into the Territorial Army but there were grave shortages of instructors and equipment. It was envisioned that the duplicating process and recruiting the required numbers of men would take no more than six months.
== Structure == Selenocysteine has the same structure as cysteine, but with an atom of selenium taking the place of the usual sulfur; it has a selenol group. Like other natural proteinogenic amino acids, cysteine and selenocysteine have L chirality in the older D/L notation based on homology to D- and L-glyceraldehyde. In the newer R/S system of designating chirality, based on the atomic numbers of atoms near the asymmetric carbon, they have R chirality, because of the presence of sulfur or selenium as a second neighbor to the asymmetric carbon. The remaining chiral amino acids, having only lighter atoms in that position, have S chirality.) Proteins which contain a selenocysteine residue are called selenoproteins. Most selenoproteins contain a single selenocysteine residue. Selenoproteins that exhibit catalytic activity are called selenoenzymes.
Sources: en.wikipedia.org
==== United States ==== As of 2023, 38 states, four territories, and the District of Columbia allow medical use of cannabis (in which THC is the primary psychoactive component), with the exception of Georgia, Idaho, Indiana, Iowa, Kansas, Nebraska, North Carolina, South Carolina, Tennessee, Texas, Wisconsin, and Wyoming. As of 2022, the federal government maintains cannabis as a schedule I controlled substance, while dronabinol is classified as Schedule III in capsule form (Marinol) and Schedule II in liquid oral form (Syndros). On 18 December 2025, President Donald Trump issued an Executive Order titled "Increasing Medical Marijuana and Cannabidiol Research", directing the DEA and FDA to reclassify medical marijuana. To that end, on 23 April 2026, the Department of Justice issued an order to immediately reclassify medical cannabis as a Schedule III controlled substance when dispensed by state-licensed cannabis dispensaries to individuals with a state issued medical marijuana card. The DEA is in the process of conducting expedited public hearings to address the broader rescheduling of all cannabis from Schedule I to Schedule III, with the hearings scheduled to begin 29 June 2026. This rescheduling makes medical marijuana legal for medicinal use when obtained from licensed dispensaries, and once the broader rescheduling is complete, should allow it to be prescribed by licensed physicians who are also licensed by the DEA to prescribed controlled substances. However, as it is still a controlled substance, diversion for recreational use will still be illegal under federal law.
The second tier consists of several dozens of midsized companies, with sales in the range of $100–$250 million per year. Their portfolios comprise both custom manufacturing and API-for-generics. They include both independents and subsidiaries of major companies. A number of these companies are privately owned and have grown mainly by reinvesting the profits. Examples are Bachem, Switzerland; Dishman, India; F.I.S. and Poli Industria Chimica, Italy; Hikal, India, and Hovione, Portugal. Customers prefer to do business with mid-sized companies, because communications are easier — they typically deal directly with the decision maker — and they can better leverage their purchasing power. The third tier includes thousands of small independents, with sales below $100 million per year. Most of them are located in Asia. They often specialize in niche technologies. The minimum economical size of a fine chemical company depends on the availability of infrastructure. If a company is located in an industrial park, where analytical services, utilities, safety, health, and environmental (SHE) services, and warehousing are readily available, there is practically no lower limit. New fine chemical plants have appeared mostly in Far East countries over the past few years. Their annual turnover rate rarely exceeds $25 million. All big and medium-size fine chemical companies have cGMP-compliant plants that are suitable for the production of pharmaceutical fine chemicals.
== Further reading == Calandre EP, Rico-Villademoros F, Slim M (2016). "Alpha2delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use". Expert Rev Neurother. 16 (11): 1263–1277. doi:10.1080/14737175.2016.1202764. PMID 27345098. S2CID 33200190.
Dimethylthiambutene (N,N-Dimethyl-1-methyl-3,3-di-2-thienylallylamine, DMTB, trade names Ohton, Aminobutene, Dimethibutin, Kobaton, Takaton, Dimethibutin) is an opioid analgesic drug, most often used in veterinary medicine in Japan and to a lesser extent in other countries in the region and around the world. It is the most prominent and widely used of the thiambutenes, a series of open-chain opioids structurally related to methadone which are also called the thienyl derivative opioids which also includes diethylthiambutene and ethylmethylthiambutene, as well as the non-opioid cough suppressant tipepidine. Dimethylthiambutene was developed in the United Kingdom in the late 1940s and introduced to the market by Burroughs-Wellcome in 1951. Dimethylthiambutene is now under international control under the UN Single Convention on Narcotic Drugs 1961, the laws governing habit-forming substances in virtually all countries and Schedule I of the US Controlled Substances Act of 1970 due to high abuse potential and never being introduced clinically in the United States; other countries regulate it much as morphine or diamorphine. Its DEA ACSCN is 9619 and it had a zero manufacturing quota in 2013.
== Structure == OcDH is a monomer with a molecular weight of 38kD made of two functionally distinct subunits. The first, Domain I, is composed of 199 amino acids and contains a Rossmann fold. Domain II is composed of 204 amino acids and is connected to the Rossmann fold of Domain I via its N-terminus.
Sources: en.wikipedia.org
Jerden later said that he was told Staley felt animosity toward him dating back to the Dirt sessions due to Jerden repeatedly recommending to Staley that he get sober. Jerden said, "Apparently he got all mad at me [during the Dirt sessions] ... And what's my job as a producer? To produce a record. I'm not getting paid to be Layne's friend". Staley was not the only one who went through heavy drug use; drummer Sean Kinney and bassist Mike Starr were both struggling with alcoholism, while the latter was also addicted to heroin. Jerden got the album's famous guitar tone by blending three different amps – a Bogner Fish preamp for the low end, a Bogner Ecstacy for the mid frequencies, and a Rockman Headphone amp for the high frequencies.
== Entrepreneurship == Mrksich has been an active entrepreneur over the past twenty years. He co-founded SAMDI Tech in 2011, which uses his label-free assay technology to perform high throughput screens for pharmaceutical companies. SAMDI Tech entered into a partnership with Charles River Laboratories in 2018 and was purchased by CRL in 2023. Mrksich also co-founded WMR Biomedical in 2008, with George Whitesides and Carmichael Roberts to develop resorbable stent materials; this company was renamed Lyra Therapeutics and had an IPO in 2020 (NASDAQ LYRA) and has drug-eluting stents in clinical trials for ear, nose and throat disease, including chronic rhinosinusitis. Mrksich has recently founded ModuMab Therapeutics, which applies his megamolecule technology to creating antibody mimics for a broad range of diseases.
=== Role in synchronized fertilization on dairy farms === By using cows that produce offspring within a one to two-week period, synchronized breeding allows dairy farmers to artificially inseminate cows for maximum pregnancy rates with minimal effort. BST is a placental lactogen (PL) hormone and falls under the class of growth hormone, or somatotropin. It is relevant to the practice of artificially expediting placental development in farm mammals, specifically dairy cattle. The mechanism through which the hormones of this somatotropin exert their effects can be observed at the cellular and molecular level in placental tissue. For mammals exposed to the hormone, bovine somatotropin associates with N-glycosylated proteins that are heavily involved in placental gestation. Knowledge of this and how BST works in conjunction with growth hormones allows for agricultural researchers to experiment on the effects of synchronization in farm animals. Synchronization involves treating cattle with a dose of BST before artificially inseminating them, according to a fixed interval schedule. Synchronization and BST treatment may be used to increase first-service pregnancy rates while following this timed artificial insemination protocol. This would therefore allow agricultural researchers to observe the effects of hormones in relation to natural estrous cycles. Dairy cattle experienced increased rates of pregnancy during synchronization when exposed to BST.
=== Early Meiji period (1868–77) === In 1854, after US Navy Commodore Matthew C. Perry forced the signing of the Treaty of Kanagawa, Japanese elites took the position that they needed to modernize the state's military capacities, or risk further coercion from Western powers, just as Qing China did in the First Opium War.
== GSNOR == The enzyme GSNO reductase (GSNOR) reduces S-nitrosoglutathione (GSNO) to an unstable intermediate, S-hydroxylaminoglutathione, which then rearranges to form glutathione sulfonamide, or in the presence of GSH, forms glutathione disulfide and hydroxylamine.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.